UPADACITINIB

upadacitinib 15 mg modified release tablet, 28

UPADACITINIB (12621G)

upadacitinib 15 mg modified release tablet, 28
12621G
Body System:
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Ankylosing spondylitis
Treatment phase: Continuing treatment

Restriction

Indication: Ankylosing spondylitis
Treatment phase: Continuing treatment - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 28 # of repeats: 5 DPMQ: $1,212.73 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Rinvoq